Healthcare
China SXT Pharmaceuticals, Inc.(SXTC)
Live Price
Offline$2.23
+0.45% today
1Y Change
-99.07%
Window
Jun 20, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- -9.7%
- EPS Growth
- -129.1%
- Dividend Yield
- 0.0%
Coverage: 244 bars ยท Jun 20, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
China SXT Pharmaceuticals, Inc. (SXTC) is a Healthcare stock with listed on NASDAQ. The stock last traded around $2.23 and down 99.1% across the available one-year price window (Jun 20, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of -9.7%, EPS growth of -129.1%, a dividend yield of 0.0%. What stands out right now is revenue -9.7%, EPS -129.1%, free cash flow -21.3% with operating margin -224.1% and ROIC -9.5%. Valuation is more restrained than many high-expectation growth names at price/sales 1.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SXTC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-9.7% vs +7.6% peer median
Operating Margin
Below sector median
-224.1% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2023 was reported on Oct 30, 2023, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -9.7% and EPS is at -129.1%, with operating margin around -224.1%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -6.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2023 Oct 30, 2023 | โ | +0.0% | -6.5% | -11.7% |
2023 Jul 17, 2023 | โ | +0.0% | -6.5% | -11.7% |
2022 Mar 31, 2022 | โ | +0.0% | -6.5% | -11.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SXTC
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SXTC Max Drawdown
-99.57%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SXTC and SPY.
Company Overview
China SXT Pharmaceuticals, Inc.
NASDAQ Capital Market
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, ShaRen, and ChenXiang. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company serves pharmaceutical companies, chain pharmacies, and hospitals, as well as pharmaceutical distributors. China SXT Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Taizhou, China.
- Leadership
- Feng Zhou
- IPO Date
- Jan 4, 2019
- Employees
- 75
- Street Address
- 178 Taidong Road North
- Mailing
- Taizhou, 225300
- Region
- Taizhou, CN
- Reporting Currency
- USD
- Investor Line
- 86 523 8629 8290
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 9.1
- Price/Sales
- 1.8
- Price/Book
- 0.2
Growth
- Revenue
- -9.7%
- EPS
- -129.1%
- Free Cash Flow
- -21.3%
Profitability
- Gross Margin
- 25.5%
- Operating Margin
- -224.1%
- Net Margin
- -274.4%
- ROE
- -14.7%
- ROIC
- -9.5%
Balance Sheet
- Debt/Equity
- 0.06
- Current Ratio
- 4.37
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.